Risk stratification according to the number of these risk factors could effectively stratify CRPC patients treated with docetaxel in terms of OS. Conclusions: Age, serum PSA level at the start of ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

or early docetaxel for hormone-sensitive disease. In addition to OS results, an update of the study's primary endpoint of prostate-specific antigen (PSA) progression-free survival showed that the ...

and docetaxel chemo led to a statistically significant improvement in overall survival (OS) compared to ADT plus docetaxel and placebo. The risk of death was significantly lower – by around 33% ...

During the study period, 79 CRPC patients received docetaxel-based chemotherapy at ... died of another cause. The median OS was 22.5 months, and the 1-year OS rate was 78.8 %.